
BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107

Overview





Information about previous performance does not guarantee future performance. **Source:** FactSet

Recent research

on sector			
Date		Headline	Download
2024/07/24	80 Jan 80 TS	Global Equity Ratings	
2024/07/12	Su 122 271 176	Global Equity Ratings	
2024/06/21	80 Jan 80 TS	Global Equity Ratings	
2024/06/14	Su 122 271 176	Global Equity Ratings	
2024/05/29	80 Jan 20 TS	Global Equity Ratings	




COMPANIES INC.



Details





Information about previous performance does not guarantee future performance. **Source:** FactSet

- CHF (-)
- CHF (-)

All listings for BAUSCH HEALTH COMPANIES INC.					
Exchange 🖨	Date	Time	Price	Trading volume (mio.)	Number of trades
Tradegate	2024/07/ 26	22:26	5.522 EUR	0.00	6
Toronto Stock Exchange	2024/07/ 26	22:15	8.30 CAD	5.85	4,176
Stuttgart	2024/07/ 26	11:05	5.365 EUR	0.00	4
SIX Swiss Exchange	2019/06/ 28	17:35	24.11 CHF	0.00	1
NYSE	2024/07/	22:00	5.99 USD	30.75	23,900



	26				
Munich	2024/07/ 26	08:02	5.472 EUR	0.00	1
Frankfurt	2024/07/ 26	08:12	5.355 EUR	0.00	2
Duesseldorf	2024/07/ 26	08:10	5.346 EUR	0.00	3
Berlin	2024/07/ 26	08:02	5.352 EUR	0.00	3



Company profile

Company Logo

BAUSCH Health

Contact Details

BAUSCH HEALTH COS. INC.

_ _

2150 St. Elzéar Boulevard West - H7L 4A8 Laval

Telefon: +1-514-744-6792

Fax: + E-mail: -

PDF Downloads

Company report: BAUSCH HEALTH COMPANIES INC.

Company Profile

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Mellipers of M	anagement board
Thomas Appio	Chairman of Managing Board
Tage Ramakrishna	Member of Executive Committee
Cees Heiman	Member of Executive Committee
Fernando Zarate	Member of Executive Committee
Graham Jackson	Member of Executive Committee
Jeff Hartness	Member of Executive Committee
Kathleen Fitzpatrick	Member of Executive Committee
Mirza Dautbegovic	Member of Executive Committee

Member of Executive

Member of Executive

Committee

Committee

Seana Carson

Tom Vadaketh

Members of Management Roard

æ,

Board of directors		
John Paulson	Chairman of Supervisory Board	
Amy Wechsler	Member of Supervisory Board	
Richard Mulligan	Member of Supervisory Board	
Brett Icahn	Member of Supervisory Board	
Christian Garcia	Member of Supervisory Board	
Frank Lee	Member of Supervisory Board	
Robert Power	Member of Supervisory Board	
Sarah Kavanagh	Member of Supervisory Board	
Steven Miller	Member of Supervisory Board	

